These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
194 related articles for article (PubMed ID: 16928815)
1. Preclinical evaluation of tumor microvascular response to a novel antiangiogenic/antitumor agent RO0281501 by dynamic contrast-enhanced MRI at 1.5 T. Muruganandham M; Lupu M; Dyke JP; Matei C; Linn M; Packman K; Kolinsky K; Higgins B; Koutcher JA Mol Cancer Ther; 2006 Aug; 5(8):1950-7. PubMed ID: 16928815 [TBL] [Abstract][Full Text] [Related]
2. Early antiangiogenic activity of SU11248 evaluated in vivo by dynamic contrast-enhanced magnetic resonance imaging in an experimental model of colon carcinoma. Marzola P; Degrassi A; Calderan L; Farace P; Nicolato E; Crescimanno C; Sandri M; Giusti A; Pesenti E; Terron A; Sbarbati A; Osculati F Clin Cancer Res; 2005 Aug; 11(16):5827-32. PubMed ID: 16115922 [TBL] [Abstract][Full Text] [Related]
3. Dynamic contrast-enhanced magnetic resonance imaging of vascular changes induced by sunitinib in papillary renal cell carcinoma xenograft tumors. Hillman GG; Singh-Gupta V; Zhang H; Al-Bashir AK; Katkuri Y; Li M; Yunker CK; Patel AD; Abrams J; Haacke EM Neoplasia; 2009 Sep; 11(9):910-20. PubMed ID: 19724685 [TBL] [Abstract][Full Text] [Related]
4. Anti-angiogenic Effects of Bumetanide Revealed by DCE-MRI with a Biodegradable Macromolecular Contrast Agent in a Colon Cancer Model. Malamas AS; Jin E; Zhang Q; Haaga J; Lu ZR Pharm Res; 2015 Sep; 32(9):3029-43. PubMed ID: 25840948 [TBL] [Abstract][Full Text] [Related]
5. In vivo assessment of antiangiogenic activity of SU6668 in an experimental colon carcinoma model. Marzola P; Degrassi A; Calderan L; Farace P; Crescimanno C; Nicolato E; Giusti A; Pesenti E; Terron A; Sbarbati A; Abrams T; Murray L; Osculati F Clin Cancer Res; 2004 Jan; 10(2):739-50. PubMed ID: 14760097 [TBL] [Abstract][Full Text] [Related]
6. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models. Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925 [TBL] [Abstract][Full Text] [Related]
7. AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging. Wilmes LJ; Pallavicini MG; Fleming LM; Gibbs J; Wang D; Li KL; Partridge SC; Henry RG; Shalinsky DR; Hu-Lowe D; Park JW; McShane TM; Lu Y; Brasch RC; Hylton NM Magn Reson Imaging; 2007 Apr; 25(3):319-27. PubMed ID: 17371720 [TBL] [Abstract][Full Text] [Related]
8. SKLB610: a novel potential inhibitor of vascular endothelial growth factor receptor tyrosine kinases inhibits angiogenesis and tumor growth in vivo. Cao ZX; Zheng RL; Lin HJ; Luo SD; Zhou Y; Xu YZ; Zeng XX; Wang Z; Zhou LN; Mao YQ; Yang L; Wei YQ; Yu LT; Yang SY; Zhao YL Cell Physiol Biochem; 2011; 27(5):565-74. PubMed ID: 21691074 [TBL] [Abstract][Full Text] [Related]
9. Integrin αvβ3-targeted dynamic contrast-enhanced magnetic resonance imaging using a gadolinium-loaded polyethylene gycol-dendrimer-cyclic RGD conjugate to evaluate tumor angiogenesis and to assess early antiangiogenic treatment response in a mouse xenograft tumor model. Chen WT; Shih TT; Chen RC; Tu SY; Hsieh WY; Yang PC Mol Imaging; 2012; 11(4):286-300. PubMed ID: 22954145 [TBL] [Abstract][Full Text] [Related]
10. KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties. Nakamura K; Taguchi E; Miura T; Yamamoto A; Takahashi K; Bichat F; Guilbaud N; Hasegawa K; Kubo K; Fujiwara Y; Suzuki R; Kubo K; Shibuya M; Isae T Cancer Res; 2006 Sep; 66(18):9134-42. PubMed ID: 16982756 [TBL] [Abstract][Full Text] [Related]
11. Dynamic Contrast-Enhanced Magnetic Resonance Imaging as Imaging Biomarker for Vascular Normalization Effect of Infigratinib in High-FGFR-Expressing Hepatocellular Carcinoma Xenografts. Tran A; Koh TS; Prawira A; Ho RZW; Le TBU; Vu TC; Hartano S; Teo XQ; Chen WC; Lee P; Thng CH; Huynh H Mol Imaging Biol; 2021 Feb; 23(1):70-83. PubMed ID: 32909245 [TBL] [Abstract][Full Text] [Related]
12. Spatiotemporal heterogeneity of tumor vasculature during tumor growth and antiangiogenic treatment: MRI assessment using permeability and blood volume parameters. Kim C; Suh JY; Heo C; Lee CK; Shim WH; Park BW; Cho G; Lee DW; Woo DC; Kim SY; Kim YJ; Bae DJ; Kim JK Cancer Med; 2018 Aug; 7(8):3921-3934. PubMed ID: 29983002 [TBL] [Abstract][Full Text] [Related]
13. Acute vascular response to cediranib treatment in human non-small-cell lung cancer xenografts with different tumour stromal architecture. Jiang Y; Allen D; Kersemans V; Devery AM; Bokobza SM; Smart S; Ryan AJ Lung Cancer; 2015 Nov; 90(2):191-8. PubMed ID: 26323213 [TBL] [Abstract][Full Text] [Related]
14. Dynamic contrast-enhanced magnetic resonance imaging rapidly indicates vessel regression in human squamous cell carcinomas grown in nude mice caused by VEGF receptor 2 blockade with DC101. Kiessling F; Farhan N; Lichy MP; Vosseler S; Heilmann M; Krix M; Bohlen P; Miller DW; Mueller MM; Semmler W; Fusenig NE; Delorme S Neoplasia; 2004; 6(3):213-23. PubMed ID: 15153333 [TBL] [Abstract][Full Text] [Related]
15. Assessment of vascular remodeling under antiangiogenic therapy using DCE-MRI and vessel size imaging. Zwick S; Strecker R; Kiselev V; Gall P; Huppert J; Palmowski M; Lederle W; Woenne EC; Hengerer A; Taupitz M; Semmler W; Kiessling F J Magn Reson Imaging; 2009 May; 29(5):1125-33. PubMed ID: 19388117 [TBL] [Abstract][Full Text] [Related]
16. Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects. Abdollahi A; Lipson KE; Sckell A; Zieher H; Klenke F; Poerschke D; Roth A; Han X; Krix M; Bischof M; Hahnfeldt P; Grone HJ; Debus J; Hlatky L; Huber PE Cancer Res; 2003 Dec; 63(24):8890-8. PubMed ID: 14695206 [TBL] [Abstract][Full Text] [Related]
17. Gadopentetate dimeglumine versus ultrasmall superparamagnetic iron oxide for dynamic contrast-enhanced MR imaging of tumor angiogenesis in human colon carcinoma in mice. de Lussanet QG; Backes WH; Griffioen AW; van Engelshoven JM; Beets-Tan RG Radiology; 2003 Nov; 229(2):429-38. PubMed ID: 14595147 [TBL] [Abstract][Full Text] [Related]
18. Dynamic contrast-enhanced magnetic resonance imaging at 1.5 Tesla with gadopentetate dimeglumine to assess the angiostatic effects of anginex in mice. de Lussanet QG; Beets-Tan RG; Backes WH; van der Schaft DW; van Engelshoven JM; Mayo KH; Griffioen AW Eur J Cancer; 2004 May; 40(8):1262-8. PubMed ID: 15110892 [TBL] [Abstract][Full Text] [Related]